Microsoft Corp MSFT backed OpenAI, in partnership with startup Color Health, has unveiled a new initiative to harness artificial intelligence in enhancing cancer screening and treatment plans.
This collaboration integrates OpenAI’s AI models into healthcare applications, marking an advancement in medical technology.
The initiative leverages OpenAI’s GPT-4o model through an AI assistant dubbed ‘copilot,’ designed to aid physicians in formulating cancer screening and pre-treatment plans. This tool aims to improve the efficiency and accuracy of medical services provided to cancer patients, according to a report from The Wall Street Journal.
Othman Laraki, co-founder and CEO of Color Health, emphasized that the copilot is intended to support doctors by enhancing their decision-making processes, rather than replacing them.
Color Health initiated the development of the copilot last year as part of its broader strategy to integrate more AI tools into healthcare.
The collaboration also extends to Moderna Inc MRNA and involves OpenAI’s efforts to automate tasks in clinical trials and other business operations.
The copilot utilizes OpenAI’s APIs to analyze extensive patient data, including risk factors and family history, alongside established clinical guidelines to generate tailored cancer screening schedules.
This assists primary care physicians, who often lack the time or expertise for detailed risk-adjusted screenings, by providing them with comprehensive, actionable insights.
Moreover, the copilot facilitates the assembly of detailed pre-treatment plans that include necessary imaging and lab tests, helping to expedite the treatment process.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.